EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
The diagnosis and treatment of prostate cancer: a review
Importance Prostate cancer is the most common cancer diagnosis made in men with more
than 160 000 new cases each year in the United States. Although it often has an indolent …
than 160 000 new cases each year in the United States. Although it often has an indolent …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, J Bellmunt, M Bolla, E Briers… - European urology, 2017 - Elsevier
Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …
[HTML][HTML] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority …
D Dearnaley, I Syndikus, H Mossop, V Khoo… - The Lancet …, 2016 - thelancet.com
Background Prostate cancer might have high radiation-fraction sensitivity that would give a
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
[HTML][HTML] GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy
Radiotherapy is one of the curative treatment options for localized prostate cancer (PCa).
The curative potential of radiotherapy is mediated by irradiation-induced oxidative stress …
The curative potential of radiotherapy is mediated by irradiation-induced oxidative stress …
Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial
G Arcangeli, B Saracino, S Arcangeli… - Journal of Clinical …, 2017 - ascopubs.org
Purpose To report the final results on treatment outcomes of a randomized trial comparing
conventional and hypofractionated radiotherapy in high-risk, organ-confined prostate cancer …
conventional and hypofractionated radiotherapy in high-risk, organ-confined prostate cancer …
Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers
TA Lawrie, JT Green, M Beresford… - Cochrane Database …, 2018 - cochranelibrary.com
Background An increasing number of people survive cancer but a significant proportion
have gastrointestinal side effects as a result of radiotherapy (RT), which impairs their quality …
have gastrointestinal side effects as a result of radiotherapy (RT), which impairs their quality …
[HTML][HTML] Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure
Neuroendocrine differentiation (NED) in prostate cancer is a well-recognized phenotypic
change by which prostate cancer cells transdifferentiate into neuroendocrine-like (NE-like) …
change by which prostate cancer cells transdifferentiate into neuroendocrine-like (NE-like) …
[HTML][HTML] Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient …
A Wilkins, H Mossop, I Syndikus, V Khoo… - The Lancet …, 2015 - thelancet.com
Summary Background Patient-reported outcomes (PROs) might detect more toxic effects of
radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to …
radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to …